NSCLC Gained Seven Approvals In May; More Are in Pipeline
When the FDA approved Novartis Pharmaceuticals Corp.’s Tabrecta (capmatinib) on May 6, it was the first of seven approvals in non-small cell lung cancer (NSCLC) through May 29 (RSP 6/20, p. 8). While these will offer more options for people with certain forms of the condition, more treatments are still needed, says one industry expert, and the pipeline is full of an array of therapies.
Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. NSCLC makes up 84% of all lung cancers, while small cell lung cancer makes up about 13%.
Study Finds Fertility Program Prevents Medication Waste, Loss, Missed DosesREAD MORE
New FDA Approvals: FDA Expands Patient Population of Takeda’s HyQviaREAD MORE